TTK Healthcare Ltd

₹ 1,115 -1.67%

11 Sep - close price

ttkhealthcare.com BSE: 507747 NSE: TTKHLTCARE

About

TTK Healthcare Ltd is a standalone TTK Group company in consumer /OTC brands, animal health, medical devices, condoms/sexual-wellness and ready-to-fry foods. Human
Pharma was divested in May 2022;
agreements to sell EVA and Good
Home were signed in July 2026.^[1]^[2]

Key Points

Business Segments:
a) Consumer Products:^[1]
The company markets and distributes
products that transcend categories; baby
care (Woodward’s Gripe Water), personal
care (Eva Deodrants), home care- room &
air fresheners (Good Home), and sexual
wellness (Skore).
The Woodward's Gripe Water is one of the oldest FMCG brands worldwide and is a market leader in the Indian colic market. It has been marketed in India since 1928. It has a distribution network of 27 warehouses, 2,600+ distributors, 650+ frontline sales teams, and a reach of ~4 lakh outlets across India. ^[2]
b) Protective Devices:^[3]
The company is one of the key players in the Indian condom Industry. It sells products under its own brand SKORE. It also owns Love Depot; digital-first platform for Pleasure Products and has another brand called MsChief.
c) Foods Business:
Fryums makes cereal-, potato-, rice-,
pulse- and corn-based pellets/papads
in 30+ shapes for B2B/institutional, exports
and selected retail/modern trade/e-commerce. FY26 Foods revenue grew 14% to ₹150.4 Cr. Hosakote/Jaipur website-stated capacity is 21,000 MT.
d) Animal Welfare Division:^[4]
AWD serves livestock, poultry, aquaculture
and pets with feed supplements, liver /fertility products, antibiotics, antiparasitic, enzymes, therapeutics and pet care through Bovianim, Gallus, Aquanim and Companim; key brands include Orcal-P, Tefroli, Ossomin, Nutrivel and Hug&Wag. The network covers 9,000+ veterinarians/900+ stockists.^[5]
e) Medical Devices Business :
-Ortho makes knee /hip replacement systems including Buechel-Pappas knees, Transition /Altius hips and Citius fixed-bearing knees.
In FY26 revenue grew by 27% to ₹77 Cr
and ~350 Citius surgeries were completed
in selected markets.
-Heart Valve makes TTK Chitra valves and distributes CardiaMed. The FY26 revenue
was ₹29.8cr (+2%).
-The improved-TC2 40-patient pilot completed three-year follow-up; a proposed ~400-patient pivotal study awaits funding /regulatory approvals.
-Management plans nationwide Citius rollout, Chrompet expansion/automation and new revision-hip, Fortius, ankle and unicondylar systems. ^[6]

Website BSE NSE

Market Cap ₹ 1,576 Cr.
Current Price ₹ 1,115
High / Low ₹ 1,255 / 735
Stock P/E 20.6
Book Value ₹ 789
Dividend Yield 0.90 %
ROCE 8.04 %
ROE 6.30 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 20.4%

Cons

Company has a low return on equity of 6.54% over last 3 years.
Earnings include an other income of Rs.66.9 Cr.
Working capital days have increased from 86.1 days to 161 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Diversified Diversified Diversified Diversified

Part of BSE Industrials

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	202	186	184	181	208	198	205	190	226	204	209	218	258
	192	176	179	169	201	190	197	178	224	198	202	207	243
Operating Profit	10	10	5	12	7	8	8	12	3	5	7	11	15
OPM %	5.0%	5%	2.9%	7%	3.3%	4.2%	3.8%	6%	1.2%	2.6%	3.4%	5%	6%
	15	16	16	16	37	18	18	13	18	19	10	21	17
Interest	1	1	0	1	1	1	1	1	1	1	1	1	1
Depreciation	3	3	3	3	2	2	2	2	2	2	2	2	2
Profit before tax	21	22	18	24	41	23	23	22	18	21	14	30	29
Tax %	24%	26%	27%	25%	23%	26%	26%	26%	26%	4%	25%	26%	26%
	16	16	13	18	32	17	17	16	13	20	11	22	21
EPS in Rs	11.09	11.33	9.12	12.93	22.35	12.17	11.84	11.43	9.20	14.43	7.45	15.40	15.06
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	483	519	528	578	628	646	476	599	725	753	801	857	888
	453	478	489	535	578	617	457	577	694	715	767	831	850
Operating Profit	30	40	38	43	50	28	19	22	31	37	35	26	38
OPM %	6%	8%	7%	7%	8%	4.4%	4.1%	3.6%	4.3%	5.0%	4.3%	3.0%	4.3%
	7	6	6	8	8	9	28	42	643	63	85	68	67
Interest	4	3	3	5	3	3	2	3	5	3	3	3	3
Depreciation	6	7	12	15	15	14	13	13	13	13	8	9	9
Profit before tax	26	36	29	30	39	19	32	48	657	84	108	83	94
Tax %	39%	36%	36%	40%	38%	37%	-44%	13%	3%	25%	25%	20%
	16	23	19	18	24	12	46	42	640	63	82	66	74
EPS in Rs	20.81	29.19	24.13	12.86	17.25	8.72	32.87	29.43	452.72	44.47	57.79	46.48	52.34
Dividend Payout %	22%	17%	21%	39%	29%	34%	18%	34%	2%	22%	17%	22%

Compounded Sales Growth
10 Years:	5%
5 Years:	12%
3 Years:	6%
TTM:	8%

Compounded Profit Growth
10 Years:	12%
5 Years:	11%
3 Years:	-52%
TTM:	14%

Stock Price CAGR
10 Years:	1%
5 Years:	10%
3 Years:	-2%
1 Year:	-6%

Return on Equity
10 Years:	19%
5 Years:	22%
3 Years:	7%
Last Year:	6%

Balance Sheet

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	8	14	14	14	14	14	14	14	14	14
Reserves	110	128	150	219	237	235	281	316	939	987	1,051	1,101
	42	38	23	47	29	30	19	22	27	23	24	24
	115	128	104	127	136	152	180	207	189	183	192	190
Total Liabilities	275	303	285	407	416	431	494	559	1,170	1,206	1,281	1,329
	52	106	99	110	98	89	85	80	71	75	81	73
CWIP	46	1	0	1	2	9	0	0	3	1	0	1
Investments	0	10	9	9	13	9	13	15	13	13	11	9
	177	185	177	288	304	325	395	463	1,083	1,118	1,189	1,246
Total Assets	275	303	285	407	416	431	494	559	1,170	1,206	1,281	1,329

Cash Flows

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	39	37	18	25	17	20	96	45	-25	-5	-4	-21
	-49	-27	5	-22	10	-13	-77	-30	32	28	20	52
	3	-11	-23	-7	-31	-10	-17	-10	-12	-22	-18	-18
Net Cash Flow	-7	-0	0	-4	-4	-4	2	5	-6	2	-2	13
Free Cash Flow	-10	21	12	21	13	8	95	42	-36	-15	6	-25
CFO/OP	176%	122%	67%	84%	62%	108%	391%	248%	-28%	54%	68%	-31%

Ratios

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	34	33	24	35	47	43	46	33	46	42	41	47
Inventory Days	62	66	65	80	77	101	123	102	89	105	107	98
Days Payable	50	53	100	130	101	121	170	134	116	110	106	83
Cash Conversion Cycle	46	46	-11	-16	22	23	-2	1	19	36	43	63
Working Capital Days	-31	-38	-24	-30	-6	-3	-32	-28	4	49	48	161
ROCE %	20%	23%	18%	15%	15%	8%	6%	8%	10%	9%	9%	8%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Consumer Products - Share of Total Revenue
% of total revenue

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	xx.xx	xx.xx	xx.xx
x	x	x		x	x		x	x	x	x
		xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
	xx	xx		xx	xx		xx		xx	xx
							xx	xx	xx	xx

Please log in to see hidden values.

Employee Strength (Permanent)
count

Foods - Share of Total Revenue
% of total revenue

Medical Devices - Share of Total Revenue
% of total revenue

Number of Manufacturing Plants
count

Protective Devices - Share of Total Revenue
% of total revenue

Number of Depots
count

Number of Countries Exported To
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%
	1.85%	1.85%	1.85%	1.87%	1.90%	1.90%	1.90%	1.89%	1.90%	1.89%	1.90%	1.86%
	3.23%	3.13%	1.14%	1.14%	1.14%	1.14%	1.14%	1.18%	1.18%	1.08%	1.11%	2.19%
	20.37%	20.46%	22.45%	22.44%	22.39%	22.39%	22.40%	22.37%	22.37%	22.46%	22.43%	21.39%
No. of Shareholders	15,672	16,651	17,221	16,930	15,762	15,780	15,899	16,112	16,134	22,481	23,686	22,809

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	65.43%	74.57%	74.56%	74.56%	74.56%	74.56%	74.57%	74.57%	74.57%	74.57%	74.57%
	5.96%	2.59%	2.26%	2.12%	1.99%	2.40%	2.38%	1.85%	1.90%	1.90%	1.86%
	4.33%	2.35%	2.35%	2.34%	2.29%	2.40%	2.99%	1.14%	1.14%	1.11%	2.19%
	24.28%	20.50%	20.83%	20.97%	21.16%	20.64%	20.07%	22.45%	22.40%	22.43%	21.39%
No. of Shareholders	13,046	12,563	12,780	13,087	12,861	15,817	15,818	17,221	15,899	23,686	22,809

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

TTK Healthcare Ltd

TTK Healthcare Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls